Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 245 Precursor Cell Lymphoblastic Leukemia-Lymphoma 143 Myelodysplastic Syndromes 142 Leukemia, Lymphocytic, Chronic, B-Cell 139 Leukemia 127 Multiple Myeloma 117 Lymphoma 115 Lymphoma, Non-Hodgkin 112 Recurrence 79 Hematologic Neoplasms 74 Melanoma 68 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67 Hodgkin Disease 67 Lymphoma, B-Cell 61 Lymphoma, Mantle-Cell 51 Lymphoma, Large B-Cell, Diffuse 50 Lymphoma, Follicular 50 Burkitt Lymphoma 41 Ovarian Neoplasms 40 Neoplasms 39 Myeloproliferative Disorders 39 Neoplasm Metastasis 34 Lymphoma, B-Cell, Marginal Zone 30 Graft vs Host Disease 29 Neoplasms, Plasma Cell 28 Carcinoma, Non-Small-Cell Lung 27 Breast Neoplasms 27 Leukemia, Biphenotypic, Acute 25 Primary Myelofibrosis 24 Anemia, Refractory, with Excess of Blasts 23

Interventions

Cyclophosphamide 2 toripalimab 1 pembrolizumab 1 fludarabine 1 apatinib 1 TP protocol 1 Surgical Procedures, Operative 1 Radiation 1 Heavy Ion Radiotherapy 1 Drug Therapy 1 Doxorubicin 1 Cisplatin 1 Carboplatin 1 AP 1903 reagent 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Thymic epithelial tumor × fludarabine × Clear all

NCT07598955 2026-05-20

SELECT-NK-THYM

Beijing Biotech

Phase 1/2 Recruiting

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡